Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 4/20 | 0.49 |
| ▸ | JAK1 | P23458 | 6/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14888542 | 0.77 | NUDT1 (0.58) | NUDT1JAK1EGLN2ALDH1A1KDM4E | |
| SCHEMBL2144688 | 0.76 | JAK1 (0.56) | JAK1EGLN2LMNAJAK3POLB | |
| SCHEMBL3302106 | 0.76 | JAK1 (0.52) | NUDT1JAK1EGLN2JAK3ALDH1A1 | |
| SCHEMBL3303549 | 0.75 | NUDT1 (0.38) | NUDT1JAK1EGLN2LMNAJAK3 | |
| SCHEMBL3300546 | 0.70 | NUDT1 (0.57) | NUDT1JAK1EGLN2JAK3KDM4E | |
| SCHEMBL17174636 | 0.69 | NUDT1 (0.51) | NUDT1JAK1EGLN2LMNAJAK3 | |
| SCHEMBL24656050 | 0.69 | NUDT1 (0.59) | NUDT1JAK1EGLN2JAK3ALDH1A1 | |
| SCHEMBL3303904 | 0.69 | NUDT1 (0.44) | NUDT1JAK1EGLN2JAK3 | |
| SCHEMBL3303902 | 0.69 | NUDT1 (0.44) | NUDT1JAK1EGLN2JAK3 | |
| SCHEMBL3593982 | 0.69 | JAK1 (0.61) | NUDT1JAK1JAK3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | NUDT1 1120/4885JAK1 69/4885EGLN2 564/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | NUDT1 1120/4885JAK1 69/4885EGLN2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.